The immunomodulator OM-89 (bacterial extract from E. coli), known to act on the immune system by modulating both humoral and cellular responses, significantly increases ACTH and glucocorticoids secretion in normal Wistar rats. A comparative administration of IL-1 displays a similar pattern of release. Moreover, OM-89-induced responses are blocked by IL-1ra, the soluble receptor antagonist of IL-1. The effect of OM-89 can thus be explained, at least in part, via IL-1 which directly enhances the secretion of both stress hormones. Finally, a comparative experiment between control and stressed rats (by immobilization) shows that the responses to OM-89 measured in this study (ACTH and corticosterone secretion) are stress-modulated.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/s0192-0561(97)00051-9 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Advances in Bacterial Lysate Immunotherapy for Infectious Diseases and Cancer.
J Immunol Res
July 2024
School of Pharmacy and Medical Sciences Griffith University, Gold Coast 4222, QLD, Australia.
Article Synopsis
- Bacterial lysates contain immunostimulants that can boost both local and systemic immune responses, aiding in the treatment of infectious diseases and potentially cancer.
- The review discusses various commercially available bacterial lysates, such as OM-85 and OM-89, showing effectiveness in managing respiratory and urinary tract infections with minimal side effects.
- Additionally, bacterial lysates may enhance innate immunity for cancer treatment, with research suggesting their potential as adjuvants in therapies for different types of cancer, including bladder cancer and sarcomas.
Non-Antibiotic Prophylaxis for Recurrent UTIs in Neurogenic Lower Urinary Tract Dysfunction (NAPRUN): Study Protocol for a Prospective, Longitudinal Multi-Arm Observational Study.
Methods Protoc
May 2023
Department of Urology, University College London Hospitals, London W1G 8PH, UK.
Introduction: Patients with neurogenic lower urinary tract dysfunction (NLUTD) reliant on intermittent self-catheterization for bladder emptying are at an increased risk of recurrent urinary tract infections (rUTI). So far, the most common practice in the prevention of rUTIs is long-term low-dose antibiotic prophylaxis, phytotherapy, and immunomodulation, whereby antibiotic prophylaxis inevitably leads to the emergence of drug-resistant pathogens and difficulty in treating infections. Therefore, non-antibiotic alternatives in the prevention of rUTIs are urgently required.
View Article and Find Full Text PDFUrinary tract infection in women.
Prz Menopauzalny
April 2021
Department of Obstetrics and Gynaecology Didactics, Faculty of Health Sciences, Medical University of Warsaw, Warsaw, Poland.
Urinary tract infection (UTI) is one of the most common infections afflicting women. UTI often accompanies vaginal infections and is frequently caused by pathogens originating in the digestive tract. The paper discusses the prevalence of UTI in various patient populations, including postmenopausal, pregnant, diabetic, epileptic, and perioperative female patients.
View Article and Find Full Text PDFCharacteristics and outcomes of overlap myositis: a comparative multigroup cohort study in adults from the MyoCite cohort.
Rheumatol Int
March 2021
Department of Clinical Immunology and Rheumatology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, 226014, India.
Overlap myositis (OM), an important subset of idiopathic inflammatory myopathies (IIM), is being increasingly recognized with wider myositis-specific autoantibody (MSA) testing. We studied the differences in clinical characteristics and long-term outcomes of OM with Dermatomyositis (DM), Polymyositis (PM), anti-synthetase syndrome (ASSD), and Cancer-associated IIM (CAM). Data from the MyoCite registry (Dec2017-May2020), a prospective dataset of IIM was extracted for the clinical profile, and MSAs, immunosuppressants received, disease activity (relapses and incomplete response), and treatment-related (drugs ADRs and infections) adverse events (DRAE and TRAE) were collected and analyzed between groups.
View Article and Find Full Text PDFImmunotherapy to reduce frequency of urinary tract infections in people with neurogenic bladder dysfunction; a pilot randomised, placebo-controlled trial.
Clin Rehabil
December 2020
Consultant in Spinal Cord Injuries, National Spinal Injury Centre (NSIC), Stoke Mandeville Hospital, Buckinghamshire Healthcare NHS Trust, Aylesbury, Bucks, UK.
Objective: To establish the feasibility of a randomized, placebo-controlled trial to investigate the effect of a specific immunotherapy bacterial lysate OM-89 (Uro-Vaxom) in reducing the frequency of urinary tract infections in people with neurogenic bladder dysfunction.
Design: A parallel-group, double-blind, randomized, placebo-controlled trial.
Setting: Patients at home, recruited through out-patient contact, social media and patient support groups.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!